Ulcerative Colitis

Kriya—Hindu for "action," he tells me—is principally a sit-down affair, ideal for early morning, with none of the frantic leaping and twirling that characterizes yoga in the West.

You begin by scrunching up your toes, then rotating your ankles, and very incrementally progress toward headstands and backbends.

Punctuating the postures are forms of pranayama breathing, or "victorious breath," a rudiment of most yoga practices.

Every day after class, Prakash guarantees my attendance the next morning with grand claims about his discipline, equating Kriya yoga with perfect everlasting good health.

"You do Kriya yoga every day," he tells me, "you have no problem.""And if I already have a problem?

" I once venture to inquire.

"Like a neck or shoulder injury?

Will yoga fix it?

" Though I remain his only student, Prakash has displayed no great interest in my personal needs.

Or maybe my sentences are too ornate, for instead of answering, he repeats his original claim: "Yoga every day, no problem.

No sciatica, no tendonitis, no insomnia, no glandular problem, no sexual problem.

You understand?

No problem."A few days later, I pose the same question to an Israeli Iyengar teacher on the opposite bank of the Ganges.

If I spend the next year in downward-facing dog, will the bulging disks in my neck vanish?

Will I one day be ...

For $25 per person, $45 per couple and $8 per child, participants can ski, eat pasta, dance to DJ music and bid on items in a silent auction.Donaldson will be there.

She should be feeling relatively well that day — it’s an off-week on her chemo calendar.

Every other Wednesday, for the last four months, a nurse at the Cancer Treatment Center has hooked up Donaldson’s portal to a machine that delivers FOLFOX and Avastin into her veins.

While her body absorbs the drugs, she sits in the reclining chair and records her intake in a diary.

At first, Donaldson can carry on a lively conversation, but after 20 minutes or so, her fatigue becomes apparent.“My body’s fighting a battle in there,” she says.

“Cancer drugs aren’t discretionary about what t...

Ltd.

for the development of a fully human anti-PD-1 antibody for the potential treatment of cancer; - Enhancing our oncology pipeline and creating partnership opportunities with the unveiling of our proprietary Ultra-Potent Toxin(TM) technology for creating antibody-toxin conjugates; and - Completing the redemption and related conversion of approximately $147.0 million of 4.25% Convertible Senior Notes due August 15, 2010 into Medarex common stock.

"2005 was an exciting year for Medarex as we and our partners continued to broaden the pipeline by advancing products into Phase III clinical trials and moving new products into clinical development," said Donald L.

Drakeman, President and CEO of Medarex.

"Additionally, we continued to execute on our business strategy by collaborating with new partners, announcing positive clinical data at key scientific and medical conferences and expanding our antibody technology to include toxin conjugates.

We were honored to have be...